- Home
- ADTX
ADTX
Aditxt Inc.
as 12-18-2024 2:30pm EST
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | RICHMOND |
| Market Cap: | 5.3M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -845.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.25 - $338.80 | Next Earning Date: | 11-18-2024 |
| Revenue: | $212,107 | Revenue Growth: | -71.70% |
| Revenue Growth (this year): | 95.61% | Revenue Growth (next year): | 1584.79% |
Stock Insider Trading Activity of Aditxt Inc. (ADTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | ADTX | 10% Owner | Oct 15 '24 | Buy | $1.50 | 15,636 | $23,454.00 | 25,434 | |
| HRT FINANCIAL LP | ADTX | 10% Owner | Oct 15 '24 | Sell | $1.17 | 25,534 | $29,874.78 | 0 |
Latest Aditxt Inc. News
ADTX Breaking Stock News: Dive into ADTX Ticker-Specific Updates for Smart Investing
Business Wire
6 days ago
Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials
GlobeNewswire
a month ago
Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.
PR Newswire
a month ago
Evofem Biosciences Announces Financial Results for the Third Quarter of 2024
GlobeNewswire
a month ago
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025
Business Wire
a month ago
Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
Business Wire
a month ago
Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
GlobeNewswire
a month ago
Appili Therapeutics Announces Results of Special Meeting of Shareholders
Business Wire
a month ago
Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
Compare ADTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADTX Aditxt Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.